Vericel (NASDAQ:VCEL) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Vericel (NASDAQ:VCEL) from a hold rating to a buy rating in a research report report published on Saturday morning.

VCEL has been the topic of a number of other reports. BTIG Research lowered Vericel from a “buy” rating to a “neutral” rating in a report on Wednesday, September 17th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Vericel in a report on Wednesday, October 8th. Zacks Research upgraded shares of Vericel from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 14th. Canaccord Genuity Group reduced their price objective on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research report on Friday, August 1st. Finally, Truist Financial decreased their price objective on Vericel from $46.00 to $41.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.20.

Vericel Stock Performance

NASDAQ VCEL opened at $38.99 on Friday. The stock has a 50-day simple moving average of $33.83 and a 200 day simple moving average of $37.69. Vericel has a twelve month low of $29.24 and a twelve month high of $63.00. The stock has a market capitalization of $1.97 billion, a PE ratio of 324.94 and a beta of 1.41.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.12. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $64.57 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The firm’s revenue for the quarter was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.02) EPS. Vericel has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Vericel will post 0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

Institutional investors and hedge funds have recently made changes to their positions in the company. Ameritas Advisory Services LLC bought a new stake in Vericel in the 2nd quarter worth approximately $30,000. Abich Financial Wealth Management LLC bought a new position in shares of Vericel during the 3rd quarter valued at approximately $31,000. CWM LLC lifted its stake in Vericel by 101.3% in the second quarter. CWM LLC now owns 1,379 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 694 shares during the last quarter. AlphaQuest LLC purchased a new stake in shares of Vericel during the second quarter valued at $60,000. Finally, Osaic Holdings Inc. increased its holdings in Vericel by 13.7% during the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 353 shares during the period.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.